RINGATIL RINGATIL ZAFON RAPID ZAFON RAPID XIKA RAPID NOXFLAM NOXFLAM NOXFLAM NOXFLAM XONI-FAST SCITAB SCITAB SCITAB SCITAB SPEDICAM XEFAST XEFAST ACABEL ACABEL ACABEL VILTAZ LORICAM LORICAM LORCAM XEFO XEFO LORNOX LORNOX VICTRA VICTRA LORNEX

Dose: 8 to 24 mg
Single Dose: 16 (16)
Frequency: As recommended.
Route: IVor IM
Instructions: limited upto two days, for treatment of osteo arthritis and rheumatoid arthritis

Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group

belongs to NSAID, oxicam group. It belongs to Cyclo-oxygenase inhibitor pharmacological group on the basis of mechanism of action. The Molecular Weight of Lornoxicam is 371.82. Its pKa is 13.63.

Lornoxicam is contraindicated in conditions like Hypovolaemia,Peptic ulcer,Cardiac insufficiency,Hypersensitivity,Pregnancy,Lactation,Gastrointestinal hemorrhage,Severe renal impairment,Dehydration,Hepatic impairment,Cerebrovascular hemorrhage.

The severe or irreversible adverse effects of Lornoxicam, which give rise to further complications include Anemia, Anemia, Thrombocytopenia, Skin reactions, Leucopenia, Hypertension, Palpitation, Anemia, Hypersensitivity.Lornoxicam produces potentially life-threatening effects which include Hypersensitivity, Gastrointestinal hemorrhage. which are responsible for the discontinuation of Lornoxicam therapy.The signs and symptoms that are produced after the acute overdosage of Lornoxicam include Nausea, Vomiting, Coma, Ataxia, Dizziness, Coagulopathy, Renal damage.The symptomatic adverse reactions produced by Lornoxicam are more or less tolerable and if they become severe, they can be treated symptomatically, these include Flatulence, Dizziness, Vertigo, Headache, Drowsiness, Diarrhea, Myalgia, Tachycardia, Constipation, Insomnia, Nervousness, Tinnitus, Abdominal pain, Dry mouth, Urticaria, Dyspepsia, Hypotension, Depression, Somnolence, Cough, Nausea and vomiting, Rhinitis, Agitation, Leg cramps, Hypertension, nervousness.

Lornoxicam is primarily indicated in conditions like Ankylosing spondylitis, Osteoarthritis, Pain, Rheumatic arthritis.

No data regarding the interactions of Lornoxicam was found.

Drug should not be given to Paediatrics, Pregnant Mothers, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Store at room temperature, .

Gastrointestinal ulceration and bleeding in medical history: Clinical monitoring at regular intervals is recommended in patients developing peptic ulceration and/or gastrointestinal bleeding while taking Lornoxicam should discontinue drug administration and with appropriate therapeutic actions being taken. Mild renal impairment (Serum creatinine 150 - 300 micro mol/L) should be monitored quarterly, patients with moderate renal impairment (Serum creatinine 300 - 700 micro mol/L) should be monitored in 1 to 2 months intervals. Careful clinical monitoring and laboratory assessment is recommended in liver diseases, blood coagulation disorders, cardiac failure. In case of long term treatment, longer than three months and in elderly patients with age greater than 65 years regular lab assessments of renal function and liver enzymes is recommended. monitor renal function in patients who are to undergo major surgery, with stressed renal function and cardiac failure and receiving concomitant diuretics treatment.